An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).Daniel Lee,Haley Gittleman,Chana Weinstock,Daniel L. Suzman,Erik Bloomquist,Sundeep Agrawal,Michael Holman Brave,Jamie Renee Brewer,Harpreet Singh,Shenghui Tang,Richard Pazdur,Julia A. Beaver,Amna Ibrahim,Laleh Amiri-KordestaniJOURNAL OF CLINICAL ONCOLOGY(2021)引用 4|浏览9暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要